Short answer
Gossamer Bio, Inc. (GOSS) filed an 8-K current report with the SEC on August 21, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), Item 1.01 (Entry into a Material Definitive Agreement). Private placement targets $25.0M initially and $125.0M at NDA acceptance, funding seralutinib development and potential commercialization.
Gossamer Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Private placement targets $25.0M initially and $125.0M at NDA acceptance, funding seralutinib development and potential commercialization
- Second closing requires FDA acceptance of the seralutinib PAH NDA during 2026, tying additional capital to a regulatory milestone
- FDA Approval Warrants could provide approximately $100.0M additional proceeds if seralutinib receives FDA approval
- Securities convert into substantial common stock at $0.14, approximately $0.187, or a five-day VWAP, creating significant dilution risk
- Stockholder approval is required, with existing investors supporting the issuance and preferred holders receiving a 4x liquidation preference before approval
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Planned Delaware charter amendments creating Series A-1, A-2 and A-3 convertible preferred stock
- Series A-1 designation targeted before the Initial Closing
- Series A-2 and A-3 designations contingent on missing stockholder approval before the Second Closing
- Preferred-stock rights and conversion terms governed by the filed certificates and Item 1.01 terms
Item 7.01 · Regulation FD Disclosure
- Press release announces Gossamer Bio’s entry into a Purchase Agreement
- Purchase Agreement represents a potentially material transaction requiring investor review of Exhibit 99.1 terms
- Transaction details, consideration and strategic impact are contained in the attached press release
Item EX-99.1 · Exhibit EX-99.1
- Up to $250M financing funds seralutinib development through potential FDA approval, reducing near-term financing risk
- $25M initial closing expected August 24, 2026, plus $125M committed upon FDA acceptance of the PAH NDA
- Additional warrants could generate up to $100M upon FDA approval at a $0.187 exercise price
- Funding depends on regulatory milestones and stockholder approval, creating execution and dilution risks
- Proceeds expected to fund operations into 2028, including PAH and PH-ILD development and commercialization preparation
Other items in this filing:
- Item 3.02: Unregistered Sales of Equity Securities
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Gossamer Bio, Inc. 8-K filings
Get the next GOSS 8-K as it lands
Follow GOSS for push alerts, or ask the research agent what this filing means.